Neurorestoration

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Airavaara, Mikko ^a   Voutilainen, Merja H ^a   Wang, Yun ^b   Hoffer, Barry ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Dopamine neurons; Neurotherapeutics; Parkinson's disease; TGF trophic factors

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CALCITRIOL; CEREBRAL DOPAMINE NEUROTROPHIC FACTOR; DIADENOSINE TETRAPHOSPHATE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; NEURTURIN; PARVOVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; COLECALCIFEROL; RETINOIC ACID;

ARTICLE; CONTINUOUS INFUSION; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG TREATMENT FAILURE; GENE THERAPY; HUMAN; MESENCEPHALON; MOTOR PERFORMANCE; NERVE CELL NECROSIS; NERVE REGENERATION; NEUROPROTECTION; NEURORESTORATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FAMILY; UNSPECIFIED SIDE EFFECT; CELL PROTECTION; DRUG DELIVERY SYSTEM; IN VITRO STUDY;

EID: 84863356004     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70045-1     Document Type: Article

References (23)

1. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-8.
2. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-94.
3. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell linederived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-2.
4. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994;182:107-11.
5. Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 1999;11:1554-66.
6. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380:252-5.
7. Bowenkamp KE, David D, Lapchak PL, Henry MA, Granholm AC, Hoffer BJ, et al. 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp Brain Res 1996;111:1-7.
8. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000;20:4686-700.
9. Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, et al. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 2009;20:511-8.
10. Brizard M, Carcenac C, Bemelmans AP, Feuerstein C, Mallet J, Savasta M. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol Dis 2006;21:90-101.
11. Smith AD, Kozlowski DA, Bohn MC, Zigmond MJ. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Exp Neurol 2005;193:420-6.
12. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-24.
13. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-95.
14. Oiwa Y, Yoshimura R, Nakai K, Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 2002;947:271-83.
15. Marks Jr WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-72.
16. Lindholm P, Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007;448:73-7.
17. Voutilainen MH, Back S, Peranen J, Lindholm P, Raasmaja A, Mannisto PT, et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp Neurol 2011;228:99-108.
18. Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, et al. CDNF protects the nigrosriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant 2011; in press.
19. Wang Y, Chang CF, Morales M, Chiang YH, Harvey BK, Su TP, et al. Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain. J Neurosci 2003;23:7958-65.
20. Wang JY, Wu JN, Cherng TL, Hoffer BJ, Chen HH, Borlongan CV, et al. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res 2001; 904:67-75.
21. Chiocco MJ, Harvey BK, Wang Y, Hoffer BJ. Neurotrophic factors for the treatment of Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl 3):S321-8.
22. Ramaswamy S, Kordower JH. Are growth factors the answer? Parkinsonism Relat Disord 2009;15(Suppl 3):S176-80.
23. Wolters ECh. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl 1): S18-23.